Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.56 (
insulin-degrading enzyme
)
737
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the investigation of the intracellular sites of insulin degradation, it might be important whether receptor-bound insulin could be a substrate for
insulin-degrading enzyme
(
IDE
).
Insulin receptor
and
IDE
were purified from rat liver using a wheat germ agglutinin column and monoclonal anti-
IDE
antibody affinity column, respectively. [125I]insulin-receptor complex was incubated with various amounts of
IDE
at 0 degree C in the presence of disuccinimidyl suberate and analyzed by reduced 7.5% SDS-PAGE and autoradiography. With increasing amounts of
IDE
, the radioactivity of 135 kd band (insulin receptor alpha-subunit) decreased, whereas that of 110 kd band (
IDE
) appeared then gradually increased, suggesting that
IDE
could bind to receptor-bound insulin. During incubation of insulin-receptor complex with
IDE
at 37 degrees C, about half of the [125I]insulin was dissociated from the complex. However, the time course of [125I]insulin degradation in this incubation was essentially identical to that of free [125I]insulin degradation. Cross-linked, non-dissociable receptor-bound [125I]insulin was also degraded by
IDE
. Rebinding studies to IM-9 cells showed that the receptor binding activity of dissociated [125I]insulin from insulin-receptor complex incubated with
IDE
was significantly (p less than 0.001) decreased as compared with that without the enzyme. These results, therefore, show that
IDE
could recognize and degrade receptor-bound insulin, and suggest that
IDE
may be involved in insulin metabolism during receptor-mediated endocytosis through the degradation of receptor-bound insulin in early neutral vesicles before their internal pH is acidified.
...
PMID:Insulin-degrading enzyme is capable of degrading receptor-bound insulin. 327 30